GABAergic drugs and Alzheimer's disease

Future Medicinal Chemistry

Volumn 3, Issue 2, 2011, Pages 149-153

  Limon, Agenor ^a   Reyes Ruiz, Jorge Mauricio ^a   Miledi, Ricardo ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; GABAERGIC RECEPTOR AFFECTING AGENT;

ALZHEIMER DISEASE; CELL DIFFERENTIATION; CELL MATURATION; DRUG TARGETING; GABAERGIC TRANSMISSION; HUMAN; NERVE CELL; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; NOTE; PRIORITY JOURNAL; PROTEIN FUNCTION; SYNAPTIC TRANSMISSION;

ALZHEIMER DISEASE; ANIMALS; BRAIN; GAMMA-AMINOBUTYRIC ACID; HUMANS; PHARMACEUTICAL PREPARATIONS; RECEPTORS, GABA;

EID: 79951654019     PISSN: 17568919     EISSN: None     Source Type: Journal    
DOI: 10.4155/fmc.10.291     Document Type: Note

References (37)

1. Orgogozo JM, Gilman S, Dartigues JF et al. Subacute meningoencephalitis in a subset of patients with Alzheimer's disease (AD) after Ab42 immunization. Neurology 61(1), 46-54 (2003). (Pubitemid 36818745)
2. Extance A. Alzheimer's failure raises questions about disease-modifying strategies. Nat. Rev. Drug Discov. 9(10), 749-751 (2010).
3. LaFerla FM, Green KN, Oddo S. Intracellular amyloid-b in Alzheimer's disease. Nat. Rev. Neurosci. 8(7), 499-509 (2007).
4. Palop JJ, Chin J, Roberson ED et al. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron 55(5), 697-711 (2007). (Pubitemid 47321079)
5. Scarmeas N, Honig LS, Choi H et al. Seizures in Alzheimer disease: who, when, and how common? Arch. Neurol. 66(8), 992-997 (2009).
6. Ittner LM, Ke YD, Delerue F et al. Dendritic function of tau mediates amyloid-b toxicity in Alzheimer's disease mouse models. Cell 142(3), 387-397 (2010).
7. Parodi J, Sepúlveda FJ, Roa J, Opazo C, Inestrosa NC, Aguayo LG. b-amyloid causes depletion of synaptic vesicles leading to neurotransmission failure. J. Biol. Chem. 285(4), 2506-2514 (2010).
8. Querfurth HW, LaFerla FM. Alzheimer's disease. N. Engl. J. Med. 362(4), 329-344 (2010).
9. Raina P, Santaguida P, Ismaila A et al. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann. Intern. Med. 148(5), 379-397 (2008). (Pubitemid 351665469)
10. Rissman RA, De Blas AL, Armstrong DM. GABA(A) receptors in aging and Alzheimer's disease. J. Neurochem. 103(4), 1285-1292 (2007). (Pubitemid 47631802)
11. Lawrence JJ. Cholinergic control of GABA release: emerging parallels between neocortex and hippocampus. Trends Neurosci. 31(7), 317-327 (2008).
12. Ellender TJ, Paulsen O. The many tunes of perisomatic targeting interneurons in the hippocampal network. Front Cell Neurosci. 30(4), pii: 26 (2010).
13. Somogyi P, Klausberger T. Defined types of cortical interneurone structure space and spike timing in the hippocampus. J. Physiol. 562(Pt 1), 9-26 (2005). (Pubitemid 40207780)
14. Sernagor E, Chabrol F, Bony G, Cancedda L. GABAergic control of neurite outgrowth and remodeling during development and adult neurogenesis: general rules and differences in diverse systems. Front. Cell Neurosci. 4, 11 (2010).
15. Olsen RW, Sieghart W. International Union of Pharmacology. LXX. Subtypes of γ-aminobutyric acid(A) receptors: classification on the basis of subunit composition, pharmacology, and function. Update. Pharmacol. Rev. 60(3), 243-260 (2008).
16. Marczynski TJ. GABAergic deafferentation hypothesis of brain aging and Alzheimer's disease revisited. Brain Res. Bull. 45(4), 341-379 (1998). (Pubitemid 28146707)
17. Dawson GR, Maubach KA, Collinson N et al. An inverse agonist selective for a5 subunit-containing GABAA receptors enhances cognition. J. Pharmacol. Exp. Ther. 316(3), 1335-1345 (2006). (Pubitemid 43345310)
18. Martin LJ, Bonin RP, Orser BA. The physiological properties and therapeutic potential of a5-GABAA receptors. BioChemSoc Trans. 37(Pt 6), 1334-1337 (2009).
19. Atack JR. Preclinical and clinical pharmacology of the GABAA receptor a5 subtype-selective inverse agonist a5IA. Pharmacol. Ther. 125(1), 11-26 (2010).
20. Farrant M, Nusser Z. Variations on an inhibitory theme: phasic and tonic activation of GABA(A) receptors. Nat. Rev. Neurosci. 6(3), 215-229 (2005). (Pubitemid 40342416)
21. Glykys J, Mann EO, Mody I. Which GABA(A) receptor subunits are necessary for tonic inhibition in the hippocampus? J. Neurosci. 28(6), 1421-1426 (2008). (Pubitemid 351231514)
22. Lee S, Yoon BE, Berglund K et al. Channel-mediated tonic GABA release from glia. Science 330(6005), 790-796 (2010).
23. Li G, Bien-Ly N, Andrews-Zwilling Y et al. GABAergic interneuron dysfunction impairs hippocampal neurogenesis in adult apolipoprotein E4 knockin mice. Cell Stem Cell 5(6), 634-645 (2009).
24. Mestas J, Hughes CC. Of mice and not men: differences between mouse and human immunology. J. Immunol. 172(5), 2731-2738 (2004). (Pubitemid 38263654)
25. Maloney B, Ge YW, Alley GM, Lahiri DK. Important differences between human and mouse APOE gene promoters: limitation of mouse APOE model in studying Alzheimer's disease. J. Neurochem. 103(3), 1237-1257 (2007). (Pubitemid 47568735)
26. Iwakiri M, Mizukami K, Ikonomovic MD, Ishikawa M, Abrahamson EE, DeKosky ST. An immunohistochemical study of GABAA receptor g subunits in Alzheimer's disease hippocampus: relationship to neurofibrillary tangle progression. Neuropathology 29(3), 263-269 (2009).
27. Limon A, Reyes-Ruiz JM, Vaswani RG, Chamberlin AR, Miledi R. Kaitocephalin antagonism of glutamate receptors expressed in Xenopus oocytes. ACS Chem. Neurosci. 1(3), 175-181 (2010).
28. Inoue S. In situ Ab pores in AD brain are cylindrical assembly of Ab protofilaments. Amyloid 15(4), 223-233 (2008).
29. Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, Sabatini BL. Natural oligomers of the Alzheimer amyloid-b protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J. Neurosci. 27(11), 2866-2875 (2007). (Pubitemid 46438992)
30. Small DH, Maksel D, Kerr ML et al. The b-amyloid protein of Alzheimer's disease binds to membrane lipids but does not bind to the a7 nicotinic acetylcholine receptor. J. Neurochem. 101(6), 1527-1538 (2007). (Pubitemid 46848846)
31. Yang X, Askarova S, Lee JC. Membrane biophysics and mechanics in Alzheimer's disease. Mol. Neurobiol. 41(2-3), 138-148 (2010).
32. Miledi R, Dueñas Z, Martinez-Torres A, Kawas CH, Eusebi F. Microtransplantation of functional receptors and channels from the Alzheimer's brain to frog oocytes. Proc. Natl Acad. Sci. USA 101(6), 1760-1763 (2004). (Pubitemid 38234227)
33. Bernareggi A, Dueñas Z, Reyes-Ruiz JM, Ruzzier F, Miledi R. Properties of glutamate receptors of Alzheimer's disease brain transplanted to frog oocytes. Proc. Natl. Acad. Sci. USA 104(8), 2956-2960 (2007). (Pubitemid 46327985)
34. Palma E, Torchia G, Limatola C et al. BDNF modulates GABAA receptors microtransplanted from the human epileptic brain to Xenopus oocytes. Proc. Natl Acad. Sci. USA 102(5), 1667-1672 (2005). (Pubitemid 40209225)
35. Limon A, Reyes-Ruiz JM, Miledi R. Microtransplantation of neurotransmitter receptors from postmortem autistic brains to Xenopus oocytes. Proc. Natl Acad. Sci. USA 105(31), 10973-10977 (2008).
36. Spitzer NC. A Rosetta stone for analysis of human membrane protein function. Proc. Natl Acad. Sci. USA 105(31), 10641-10642 (2008).
37. Eusebi F, Palma E, Amici M, Miledi R. Microtransplantation of ligand-gated receptor-channels from fresh or frozen nervous tissue into Xenopus oocytes: a potent tool for expanding functional information. Prog. Neurobiol. 88(1), 32-40 (2009).